Clinical trial
A Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety and Efficacy of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)
NCT02736149 is registered in ClinicalTrials.gov with Eiger BioPharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety and Efficacy of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)
- Lead sponsor
- Eiger BioPharmaceuticals
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- December 31, 2016
- Completion date
- August 31, 2018
- Enrollment
- 51 (actual)
- Sites
- 28
Conditions
As the registry lists them; a condition with its own page is linked.